Percutaneous Ablative Therapies for the Management of Osteoid Osteomas: A Systematic Review and Meta-Analysis

Purpose To evaluate safety and efficacy of percutaneous ablative therapy for the treatment for osteoid osteomas. Materials and Methods PubMed database, Web of Science, and SCOPUS were searched from their inception until November 2019 for articles describing osteoid osteoma. Demographic data, success rates, pre- and post-procedure VAS scores, and complications were recorded. A random-effects meta-analyses of the VAS pain score at various time points were calculated. Results For radiofrequency ablation, VAS scores for pain at pre-procedure, 24–48 h, and 3–6 months yielded cumulative pain scores of 7.64 +/− 0.175, 0.78 +/− 0.186, and 0.02 +/− 0.0196, respectively. For cryoablation, VAS scores at pre-procedure, 24–48 h, and 3–6 months yielded cumulative pain scores of 8.46 +/− 0.549, 0.975 +/− 0.66, and 0.112 +/− 0.08, respectively. For laser ablation, VAS scores at pre-procedure and 24–48 h yielded cumulative pain scores of 4.94 +/− 1.42, and 0.506 +/− 0.268, respectively. For microwave ablation, VAS scores at pre-procedure, 24–48 h, and 3–6 months yielded cumulative pain scores of 6.14 +/− 1.07, 1.636 +/− 1.215, and 0 +/− 0.0, respectively. All ablation methods resulted in significant immediate and lasting pain reduction ( p